


Prevention and public health implications

GLP-1 obesity medications

Glasgow Centre for Population Health

Glasgow Centre for Population Health


1

Did you know...

GLP-1 medications

cannot be considered as a form of primary prevention, as they treat existing obesity rather than addressing its underlying determinants. Instead, they may contribute to secondary and tertiary prevention by reducing the risk of obesity-related disease, although their longer-term population health impact remains uncertain.





GLP-1 obesity medications

DID YOU KNOW?

GLP-1 obesity medications

2

These medications do not address the

underlying social, economic, commercial and environmental determinants of obesity. Their emergence therefore reinforces the importance of combining effective clinical treatment with wider population-level prevention.

Glasgow Centre for Population Health

Glasgow Centre for Population Health

3

The growing use of GLP-1 medications

may also have far-reaching implications beyond healthcare, potentially influencing food consumption, commercial food systems, social prescribing and demand for community-based services.

DID YOU KNOW?

GLP-1 obesity medications

DID YOU KNOW?

GLP-1 obesity medications

4

While evidence of these wider impacts

is still emerging, maximising the population health benefits of GLP-1 therapies will require an integrated approach combining clinical treatment, health improvement and action on the wider determinants of health.

For more information, search for ‘GLP-1’ at www.gcph.co.uk

Glasgow Centre for Population Health